Focal HIFU is a
very experimental procedure. There isn't nearly enough long term data that it should be done outside of a clinical trial. To understand the issues, including the one you mentioned, please read:
/pcnrv.blogspot.com/2016/12/focal-ablation-unresolved-issues.htmlI wonder how many of these unresolved issues were discussed with you by any of the doctors you met with.
I'll reprint the two paragraphs that are most relevant to you here:
Allen said...
Tracking progression after therapy
After radical prostatectomy, we hope that PSA will become undetectable permanently. If it rises afterwards, we suspect recurrence. After radical radiation therapy, PSA reaches a nadir, usually less than 0.5 ng/ml. If it rises 2 or more points above that, we suspect recurrence. However, with focal ablation, there is no reasonably expected PSA nadir, and there is no rise in PSA we can label as a biochemical recurrence. The PSA changes will be different for every patient. Because only the index tumor has been ablated, we don’t expect PSA from small foci of cancer outside of the ablation zone to vanish, nor PSA from BPH or prostatitis. Because PSA cannot be used to monitor remission, we have to use imaging and periodic biopsies. Such imaging and biopsies requires experienced radiologists and pathologists because ablated tissue is qualitatively different from unablated tissue.
Re-do rates
As we’ve seen, some recurrences occur within the ablation zone, but most recurrences occur outside of the treated area. In the above-cited report on HIFU, 28% of patients had a recurrence. This is typical for focal ablation. An advantage often cited for focal ablation is that patients who have a recurrence can be retreated with a second round of focal ablation therapy. In the Ahmed/Emberton HIFU study, 20% of all patients were treated multiple times (others chose radical salvage therapy (7%) or permanent hormone therapy (1%)).
“Re-do’s” incur extra costs and may increase morbidity of treatment. There’s no guarantee that they will be effective. As we’ve seen, recurrences are common even when the whole gland is ablated.